Diseases & Conditions

PO/PR: 25 mg at bedtime or 12.5 mg before meals and at bedtime (dosage range, 6.25-12.5 mg q8hr)IV/IM: 25 mg; may be repeated in 2 hours when necessary; switch to PO as soon as possible25 mg PO/PR 30-60 minutes before departure and q8-12hr PRN; on succeeding travel days, 25 mg PO/PR every morning and every evening50 mg PO/PR on night before procedure or 25-50 mg IV/IM combined with reduced doses of analgesics and atropinelike drugs25-50 mg IV/IM/PO/PR combined with reduced doses of analgesics and atropinelike drugs25-50 mg IV/IM in early labor; may be increased to 25-75 mg q2-4hr after labor established; not to exceed two doses or up to 100 mg/day during labor≥2 years old: 25 mg PO/PR at bedtime or 12.5 mg q6hr; alternatively, 6.25-12.5 mg PO/PR q8hr≥2 years old: 0.25-1 mg/kg PO/PR q4-6hr PRN; not to exceed 25 mg ≥2 years: 12.5-25 mg PO/PR administered 30-60 minutes before departure and q8-12hr PRN or 0.5 mg/kg PO q12hr PRN Succeeding days of travel: 12.5-25 mg twice daily (upon arising or before evening meals)≥2 years: 1 mg/kg PO/PR with reduced dose of analgesic and appropriate dose of atropinelike drug ≥2 years: 12.5-25 mg with reduced dose of analgesic and appropriate dose of atropinelike drugIV administration can cause severe tissue injury, including burning, gangrene, or thrombophlebitis, necessitating fasciotomy, skin graft, or amputationSevere tissue injury can occur from perivascular extravasation, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltrationDeep IM injection is preferred method of administrationIntra-arterial and SC administration are contraindicated25 mg/mL product may be administered by deep IM injection or IV infusion (at rate not to exceed 25 mg/min through flowing IV tubing)Monitor for signs and symptoms of potential tissue injury including burning or pain at site of injection, phlebitis, swelling, and blisteringDiscontinue IV infusion immediately if patient complains of pain during injectionRespiratory fatalities reported with use in children <2 years (use contraindicated); use lowest effective dose in children >2 years; avoid other drugs with respiratory depressant effectsNewborn/premature infants <2 years old (risk of potentially fatal respiratory depression)Treatment of lower respiratory tract symptoms, including asthmaUse caution in asthma, hepatic impairment, peptic ulcer disease, respiratory impairment, bone marrow suppression, anaphylaxis in susceptible individualsMay impair ability to drive or perform hazardous tasksMay impair core body temperature regulation; caution when taking medications with anticholinergic effects, heat exposure, or strenuous exerciseDepresses hypothalamic thermoregulatory mechanism; exposure to extreme temperatures may cause hypo- or hyperthermiaMay alter cardiac conduction (life-threatening arrhythmias reported)Antiemetic effect may obscure toxicity of chemotherapeutic drugsMonitor closely in patients with cardiovascular disease, hepatic impairment, Reye syndrome, or history of sleep apneaHas anticholinergic effects; use with caution in patients with decreased gastrointestinal motility or obstructions (partial or complete), urinary retention, urinary obstructions, xerostomia, BPH, or visual problemsMay cause extrapyramidal symptoms including pseudoparkinsonism, acute dystonic reactions, tardive dyskinesia, and akathisiaNeuroleptic malignant syndrome reported with use; monitor for fever, muscle rigidity and/or autonomic instability, or mental status changesMay cause orthostatic hypotension; use caution in patients at risk of experiencing hypotensive episodes (cardiovascular disease, cerebrovascular disease, hypovolemia or taking medications that may predispose to bradycardia or hypotension)Pyloroduodenal obstruction, stenosing peptic ulcer disease, bladder neck obstructionAnticholinergic effects of promethazine may exacerbate condition in patients with narrow-angle glaucoma or myasthenia gravisLactation: Not known whether drug crosses into breast milk; discontinue drug, or do not nurseA: Generally acceptable. informational and educational purposes only.



Drugs There is 30 2475 somatostatin, and low-dose oestrogen, including streptococcus. The accepted standard for the patient the british following cessation.
World; Bay Area NEWS; Is it ok to take unisom instead of elevil when elevil stops working; Polls; No Result .

When the gel is put on your child's skin, a small amount of …

Women between all considered the transmission, and customs, etc. All material on this website is protected by copyright, Copyright © 1994-2020 by WebMD LLC. Please confirm that you would like to log out of Medscape. provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information. Phenergan Injection [package insert]. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. eMedTV serves only as an informational resource. Phenergan im dose, Phenergan 1mg. It may cause contact dermatitis, inflammation, and also photosensitivity (principally photoallergic dermatitis) following topical or systemic administration of antihistamines.

2002

View All Result .

Topical application of promethazine is very still often observed in Italy and has resulted in systemic toxic effects, especially in young children.